back to cluster viewer
cluster path 10111110111111
198 words, 8,461 tokens
freq alpha suffix
Words in frequency order
1 | absolute | 6,478
|
2 | framingham | 730
|
3 | placebo-corrected | 121
|
4 | baseline-adjusted | 106
|
5 | decimal | 101
|
6 | placebo-adjusted | 83
|
7 | adp-induced | 70
|
8 | 'at | 69
|
9 | gail | 60
|
10 | n400 | 49
|
11 | placebo-subtracted | 49
|
12 | keratometric | 37
|
13 | baseline-to-endpoint | 33
|
14 | population-attributable | 32
|
15 | interocular | 31
|
16 | percentual | 22
|
17 | change-from-baseline | 18
|
18 | mehran | 15
|
19 | non-laboratory-based | 12
|
20 | incidence-density | 8
|
21 | lmtt | 8
|
22 | ramstadius | 7
|
23 | time-to-discharge | 7
|
24 | 18-segment | 6
|
25 | acuity-pci | 6
|
26 | euler | 6
|
27 | kohne | 6
|
28 | ludwigshafen | 6
|
29 | moralistic | 6
|
30 | time-wise | 6
|
31 | arm-finger | 5
|
32 | d2fs | 5
|
33 | ferg | 5
|
34 | hypocone | 5
|
35 | per-act | 5
|
36 | response-rate | 5
|
37 | sleep-quality | 5
|
38 | agonist-specific | 4
|
39 | d12fs | 4
|
40 | infit | 4
|
41 | marangoni | 4
|
42 | pre-avr | 4
|
43 | 11.1-fold | 3
|
44 | 30-y | 3
|
45 | adp-specific | 3
|
46 | aortic-to-brachial | 3
|
47 | applicational | 3
|
48 | aspirin-associated | 3
|
49 | crb-50 | 3
|
50 | free-language | 3
|
51 | hrt-related | 3
|
52 | increase/no | 3
|
53 | inter-trials | 3
|
54 | lipoprotein-mediated | 3
|
55 | medium/low | 3
|
56 | oxytocin-placebo | 3
|
57 | per-day | 3
|
58 | post-ach | 3
|
59 | post-af | 3
|
60 | postmovement | 3
|
61 | unsupportable | 3
|
62 | within-trials | 3
|
63 | ≥100-point | 3
|
64 | aaf13 | 2
|
65 | across-time | 2
|
66 | at-induced | 2
|
67 | baseline-to-end-point | 2
|
68 | beta-error | 2
|
69 | botrocetin-induced | 2
|
70 | cd38+hla-dr+ | 2
|
71 | cvd-mortality | 2
|
72 | d121.1°c | 2
|
73 | eeg-derived | 2
|
74 | gestational-related | 2
|
75 | hemorragic | 2
|
76 | ischemic/thrombembolic | 2
|
77 | magnesiothermic | 2
|
78 | mcknight | 2
|
79 | post-clopidogrel | 2
|
80 | smbg-related | 2
|
81 | snp8nrg6221533 | 2
|
82 | substituted-cysteine | 2
|
83 | week-by-week | 2
|
84 | -decline-from-peak | 1
|
85 | -relative | 1
|
86 | 0.4-percent | 1
|
87 | 1.0-unit | 1
|
88 | 1.8mmhg | 1
|
89 | 1.94× | 1
|
90 | 10-year-fracture | 1
|
91 | 10.7-mmhg | 1
|
92 | 105,375 | 1
|
93 | 11-mhz | 1
|
94 | 11.0-letter | 1
|
95 | 11.6-times | 1
|
96 | 123,479 | 1
|
97 | 17-keto-steroid | 1
|
98 | 18-percent | 1
|
99 | 18.4-fold | 1
|
100 | 18.7-fold | 1
|
101 | 18.9-point | 1
|
102 | 277,721 | 1
|
103 | 30in | 1
|
104 | 50-yr | 1
|
105 | 7.0-point | 1
|
106 | 8-bpm | 1
|
107 | 8.5-point | 1
|
108 | 8.9-mg/dl | 1
|
109 | 9.4-point | 1
|
110 | a1r-dependent | 1
|
111 | antirecurrence | 1
|
112 | bacteremia-adapted | 1
|
113 | bap/ctx | 1
|
114 | beefly | 1
|
115 | blueness | 1
|
116 | calsyntenin | 1
|
117 | chw-reported | 1
|
118 | clinical/functional | 1
|
119 | clofibrate-mediated | 1
|
120 | cmf-related | 1
|
121 | cxcl16-mediated | 1
|
122 | cxcl16-triggered | 1
|
123 | dha-mediated | 1
|
124 | dmi-placebo | 1
|
125 | edta-independent | 1
|
126 | encephaledema | 1
|
127 | endotoxin-binding | 1
|
128 | estimated14 | 1
|
129 | extrathoracically | 1
|
130 | fibrinogen-mediated | 1
|
131 | finger-thumb | 1
|
132 | fungus-induced | 1
|
133 | genetic-related | 1
|
134 | gvl-b-dl | 1
|
135 | gvl-dl | 1
|
136 | height/standard | 1
|
137 | high-on-treatment | 1
|
138 | hydrophobicity/ | 1
|
139 | hypoxia-triggered | 1
|
140 | il-8-induced | 1
|
141 | income/higher | 1
|
142 | iodixanol-associated | 1
|
143 | isoleucine-to-valine | 1
|
144 | ivig.when | 1
|
145 | lda-mediated | 1
|
146 | ldl-stimulated | 1
|
147 | lgh-induced | 1
|
148 | liald₄ | 1
|
149 | life-versus-death | 1
|
150 | lipid/hdl | 1
|
151 | lymphonodular | 1
|
152 | macrocosmal | 1
|
153 | mcid-a | 1
|
154 | meanweight | 1
|
155 | more-numerous | 1
|
156 | nanosilicate | 1
|
157 | nbt-dye | 1
|
158 | no-stimulated | 1
|
159 | non-retired-no | 1
|
160 | non-sns | 1
|
161 | oligosaccharide-binding | 1
|
162 | ot-evoked | 1
|
163 | pain/fatigue | 1
|
164 | per-couple | 1
|
165 | per-subject/per-partner | 1
|
166 | picturesque | 1
|
167 | polyglycerol/water | 1
|
168 | post-thyroglobulin | 1
|
169 | pragmatical | 1
|
170 | preload/afterload | 1
|
171 | present-value | 1
|
172 | protocol-recommended | 1
|
173 | prx-dependent | 1
|
174 | s5-1 | 1
|
175 | screening-ready | 1
|
176 | sfllrn-stimulated | 1
|
177 | target-normal | 1
|
178 | tash-induced | 1
|
179 | term.no | 1
|
180 | titer-fold | 1
|
181 | transliterated | 1
|
182 | trap-mediated | 1
|
183 | tre-tsk | 1
|
184 | tz-induced | 1
|
185 | un-discounted | 1
|
186 | unabating | 1
|
187 | unattend | 1
|
188 | unsignificicant | 1
|
189 | verbal/numeric | 1
|
190 | virally-expressed | 1
|
191 | weight/standard | 1
|
192 | wolff-kishner | 1
|
193 | ~5-fold | 1
|
194 | ω-gliadin | 1
|
195 | ≈4-fold | 1
|
196 | ≥4log | 1
|
197 | ≥70-point | 1
|
198 | ≥two-fold | 1
|
Words in alphabetical order
1 | 'at | 69
|
2 | -decline-from-peak | 1
|
3 | -relative | 1
|
4 | 0.4-percent | 1
|
5 | 1.0-unit | 1
|
6 | 1.8mmhg | 1
|
7 | 1.94× | 1
|
8 | 10-year-fracture | 1
|
9 | 10.7-mmhg | 1
|
10 | 105,375 | 1
|
11 | 11-mhz | 1
|
12 | 11.0-letter | 1
|
13 | 11.1-fold | 3
|
14 | 11.6-times | 1
|
15 | 123,479 | 1
|
16 | 17-keto-steroid | 1
|
17 | 18-percent | 1
|
18 | 18-segment | 6
|
19 | 18.4-fold | 1
|
20 | 18.7-fold | 1
|
21 | 18.9-point | 1
|
22 | 277,721 | 1
|
23 | 30-y | 3
|
24 | 30in | 1
|
25 | 50-yr | 1
|
26 | 7.0-point | 1
|
27 | 8-bpm | 1
|
28 | 8.5-point | 1
|
29 | 8.9-mg/dl | 1
|
30 | 9.4-point | 1
|
31 | a1r-dependent | 1
|
32 | aaf13 | 2
|
33 | absolute | 6,478
|
34 | across-time | 2
|
35 | acuity-pci | 6
|
36 | adp-induced | 70
|
37 | adp-specific | 3
|
38 | agonist-specific | 4
|
39 | antirecurrence | 1
|
40 | aortic-to-brachial | 3
|
41 | applicational | 3
|
42 | arm-finger | 5
|
43 | aspirin-associated | 3
|
44 | at-induced | 2
|
45 | bacteremia-adapted | 1
|
46 | bap/ctx | 1
|
47 | baseline-adjusted | 106
|
48 | baseline-to-end-point | 2
|
49 | baseline-to-endpoint | 33
|
50 | beefly | 1
|
51 | beta-error | 2
|
52 | blueness | 1
|
53 | botrocetin-induced | 2
|
54 | calsyntenin | 1
|
55 | cd38+hla-dr+ | 2
|
56 | change-from-baseline | 18
|
57 | chw-reported | 1
|
58 | clinical/functional | 1
|
59 | clofibrate-mediated | 1
|
60 | cmf-related | 1
|
61 | crb-50 | 3
|
62 | cvd-mortality | 2
|
63 | cxcl16-mediated | 1
|
64 | cxcl16-triggered | 1
|
65 | d121.1°c | 2
|
66 | d12fs | 4
|
67 | d2fs | 5
|
68 | decimal | 101
|
69 | dha-mediated | 1
|
70 | dmi-placebo | 1
|
71 | edta-independent | 1
|
72 | eeg-derived | 2
|
73 | encephaledema | 1
|
74 | endotoxin-binding | 1
|
75 | estimated14 | 1
|
76 | euler | 6
|
77 | extrathoracically | 1
|
78 | ferg | 5
|
79 | fibrinogen-mediated | 1
|
80 | finger-thumb | 1
|
81 | framingham | 730
|
82 | free-language | 3
|
83 | fungus-induced | 1
|
84 | gail | 60
|
85 | genetic-related | 1
|
86 | gestational-related | 2
|
87 | gvl-b-dl | 1
|
88 | gvl-dl | 1
|
89 | height/standard | 1
|
90 | hemorragic | 2
|
91 | high-on-treatment | 1
|
92 | hrt-related | 3
|
93 | hydrophobicity/ | 1
|
94 | hypocone | 5
|
95 | hypoxia-triggered | 1
|
96 | il-8-induced | 1
|
97 | incidence-density | 8
|
98 | income/higher | 1
|
99 | increase/no | 3
|
100 | infit | 4
|
101 | inter-trials | 3
|
102 | interocular | 31
|
103 | iodixanol-associated | 1
|
104 | ischemic/thrombembolic | 2
|
105 | isoleucine-to-valine | 1
|
106 | ivig.when | 1
|
107 | keratometric | 37
|
108 | kohne | 6
|
109 | lda-mediated | 1
|
110 | ldl-stimulated | 1
|
111 | lgh-induced | 1
|
112 | liald₄ | 1
|
113 | life-versus-death | 1
|
114 | lipid/hdl | 1
|
115 | lipoprotein-mediated | 3
|
116 | lmtt | 8
|
117 | ludwigshafen | 6
|
118 | lymphonodular | 1
|
119 | macrocosmal | 1
|
120 | magnesiothermic | 2
|
121 | marangoni | 4
|
122 | mcid-a | 1
|
123 | mcknight | 2
|
124 | meanweight | 1
|
125 | medium/low | 3
|
126 | mehran | 15
|
127 | moralistic | 6
|
128 | more-numerous | 1
|
129 | n400 | 49
|
130 | nanosilicate | 1
|
131 | nbt-dye | 1
|
132 | no-stimulated | 1
|
133 | non-laboratory-based | 12
|
134 | non-retired-no | 1
|
135 | non-sns | 1
|
136 | oligosaccharide-binding | 1
|
137 | ot-evoked | 1
|
138 | oxytocin-placebo | 3
|
139 | pain/fatigue | 1
|
140 | per-act | 5
|
141 | per-couple | 1
|
142 | per-day | 3
|
143 | per-subject/per-partner | 1
|
144 | percentual | 22
|
145 | picturesque | 1
|
146 | placebo-adjusted | 83
|
147 | placebo-corrected | 121
|
148 | placebo-subtracted | 49
|
149 | polyglycerol/water | 1
|
150 | population-attributable | 32
|
151 | post-ach | 3
|
152 | post-af | 3
|
153 | post-clopidogrel | 2
|
154 | post-thyroglobulin | 1
|
155 | postmovement | 3
|
156 | pragmatical | 1
|
157 | pre-avr | 4
|
158 | preload/afterload | 1
|
159 | present-value | 1
|
160 | protocol-recommended | 1
|
161 | prx-dependent | 1
|
162 | ramstadius | 7
|
163 | response-rate | 5
|
164 | s5-1 | 1
|
165 | screening-ready | 1
|
166 | sfllrn-stimulated | 1
|
167 | sleep-quality | 5
|
168 | smbg-related | 2
|
169 | snp8nrg6221533 | 2
|
170 | substituted-cysteine | 2
|
171 | target-normal | 1
|
172 | tash-induced | 1
|
173 | term.no | 1
|
174 | time-to-discharge | 7
|
175 | time-wise | 6
|
176 | titer-fold | 1
|
177 | transliterated | 1
|
178 | trap-mediated | 1
|
179 | tre-tsk | 1
|
180 | tz-induced | 1
|
181 | un-discounted | 1
|
182 | unabating | 1
|
183 | unattend | 1
|
184 | unsignificicant | 1
|
185 | unsupportable | 3
|
186 | verbal/numeric | 1
|
187 | virally-expressed | 1
|
188 | week-by-week | 2
|
189 | weight/standard | 1
|
190 | within-trials | 3
|
191 | wolff-kishner | 1
|
192 | ~5-fold | 1
|
193 | ω-gliadin | 1
|
194 | ≈4-fold | 1
|
195 | ≥100-point | 3
|
196 | ≥4log | 1
|
197 | ≥70-point | 1
|
198 | ≥two-fold | 1
|
Words in suffix order
1 | cd38+hla-dr+ | 2
|
2 | hydrophobicity/ | 1
|
3 | n400 | 49
|
4 | crb-50 | 3
|
5 | s5-1 | 1
|
6 | 277,721 | 1
|
7 | aaf13 | 2
|
8 | snp8nrg6221533 | 2
|
9 | estimated14 | 1
|
10 | 105,375 | 1
|
11 | 123,479 | 1
|
12 | mcid-a | 1
|
13 | encephaledema | 1
|
14 | finger-thumb | 1
|
15 | adp-specific | 3
|
16 | agonist-specific | 4
|
17 | hemorragic | 2
|
18 | ischemic/thrombembolic | 2
|
19 | magnesiothermic | 2
|
20 | verbal/numeric | 1
|
21 | keratometric | 37
|
22 | moralistic | 6
|
23 | d121.1°c | 2
|
24 | preload/afterload | 1
|
25 | il-8-induced | 1
|
26 | lgh-induced | 1
|
27 | tash-induced | 1
|
28 | botrocetin-induced | 2
|
29 | adp-induced | 70
|
30 | fungus-induced | 1
|
31 | at-induced | 2
|
32 | tz-induced | 1
|
33 | protocol-recommended | 1
|
34 | ot-evoked | 1
|
35 | cxcl16-triggered | 1
|
36 | hypoxia-triggered | 1
|
37 | non-laboratory-based | 12
|
38 | virally-expressed | 1
|
39 | iodixanol-associated | 1
|
40 | aspirin-associated | 3
|
41 | cxcl16-mediated | 1
|
42 | lda-mediated | 1
|
43 | dha-mediated | 1
|
44 | clofibrate-mediated | 1
|
45 | fibrinogen-mediated | 1
|
46 | lipoprotein-mediated | 3
|
47 | trap-mediated | 1
|
48 | genetic-related | 1
|
49 | cmf-related | 1
|
50 | smbg-related | 2
|
51 | gestational-related | 2
|
52 | hrt-related | 3
|
53 | ldl-stimulated | 1
|
54 | sfllrn-stimulated | 1
|
55 | no-stimulated | 1
|
56 | transliterated | 1
|
57 | placebo-subtracted | 49
|
58 | placebo-corrected | 121
|
59 | un-discounted | 1
|
60 | bacteremia-adapted | 1
|
61 | chw-reported | 1
|
62 | baseline-adjusted | 106
|
63 | placebo-adjusted | 83
|
64 | eeg-derived | 2
|
65 | 17-keto-steroid | 1
|
66 | 11.1-fold | 3
|
67 | 18.4-fold | 1
|
68 | ≈4-fold | 1
|
69 | ~5-fold | 1
|
70 | 18.7-fold | 1
|
71 | ≥two-fold | 1
|
72 | titer-fold | 1
|
73 | unattend | 1
|
74 | height/standard | 1
|
75 | weight/standard | 1
|
76 | antirecurrence | 1
|
77 | free-language | 3
|
78 | time-to-discharge | 7
|
79 | unsupportable | 3
|
80 | population-attributable | 32
|
81 | per-couple | 1
|
82 | across-time | 2
|
83 | kohne | 6
|
84 | substituted-cysteine | 2
|
85 | isoleucine-to-valine | 1
|
86 | change-from-baseline | 18
|
87 | hypocone | 5
|
88 | 10-year-fracture | 1
|
89 | time-wise | 6
|
90 | nanosilicate | 1
|
91 | response-rate | 5
|
92 | absolute | 6,478
|
93 | pain/fatigue | 1
|
94 | present-value | 1
|
95 | picturesque | 1
|
96 | -relative | 1
|
97 | nbt-dye | 1
|
98 | post-af | 3
|
99 | 10.7-mmhg | 1
|
100 | 1.8mmhg | 1
|
101 | oligosaccharide-binding | 1
|
102 | endotoxin-binding | 1
|
103 | unabating | 1
|
104 | ≥4log | 1
|
105 | ferg | 5
|
106 | post-ach | 3
|
107 | life-versus-death | 1
|
108 | acuity-pci | 6
|
109 | marangoni | 4
|
110 | -decline-from-peak | 1
|
111 | week-by-week | 2
|
112 | tre-tsk | 1
|
113 | pragmatical | 1
|
114 | aortic-to-brachial | 3
|
115 | decimal | 101
|
116 | target-normal | 1
|
117 | macrocosmal | 1
|
118 | applicational | 3
|
119 | clinical/functional | 1
|
120 | percentual | 22
|
121 | gvl-b-dl | 1
|
122 | gvl-dl | 1
|
123 | 8.9-mg/dl | 1
|
124 | lipid/hdl | 1
|
125 | post-clopidogrel | 2
|
126 | gail | 60
|
127 | framingham | 730
|
128 | 8-bpm | 1
|
129 | mehran | 15
|
130 | ludwigshafen | 6
|
131 | ivig.when | 1
|
132 | 30in | 1
|
133 | ω-gliadin | 1
|
134 | post-thyroglobulin | 1
|
135 | calsyntenin | 1
|
136 | dmi-placebo | 1
|
137 | oxytocin-placebo | 3
|
138 | non-retired-no | 1
|
139 | term.no | 1
|
140 | increase/no | 3
|
141 | interocular | 31
|
142 | lymphonodular | 1
|
143 | arm-finger | 5
|
144 | income/higher | 1
|
145 | euler | 6
|
146 | wolff-kishner | 1
|
147 | per-subject/per-partner | 1
|
148 | polyglycerol/water | 1
|
149 | 11.0-letter | 1
|
150 | beta-error | 2
|
151 | pre-avr | 4
|
152 | 50-yr | 1
|
153 | 11.6-times | 1
|
154 | d12fs | 4
|
155 | d2fs | 5
|
156 | within-trials | 3
|
157 | inter-trials | 3
|
158 | non-sns | 1
|
159 | blueness | 1
|
160 | ramstadius | 7
|
161 | more-numerous | 1
|
162 | 'at | 69
|
163 | per-act | 5
|
164 | meanweight | 1
|
165 | mcknight | 2
|
166 | infit | 4
|
167 | 1.0-unit | 1
|
168 | unsignificicant | 1
|
169 | 0.4-percent | 1
|
170 | 18-percent | 1
|
171 | a1r-dependent | 1
|
172 | prx-dependent | 1
|
173 | edta-independent | 1
|
174 | postmovement | 3
|
175 | 18-segment | 6
|
176 | high-on-treatment | 1
|
177 | 7.0-point | 1
|
178 | ≥100-point | 3
|
179 | ≥70-point | 1
|
180 | 9.4-point | 1
|
181 | 8.5-point | 1
|
182 | 18.9-point | 1
|
183 | baseline-to-end-point | 2
|
184 | baseline-to-endpoint | 33
|
185 | lmtt | 8
|
186 | medium/low | 3
|
187 | bap/ctx | 1
|
188 | 30-y | 3
|
189 | per-day | 3
|
190 | screening-ready | 1
|
191 | beefly | 1
|
192 | extrathoracically | 1
|
193 | cvd-mortality | 2
|
194 | sleep-quality | 5
|
195 | incidence-density | 8
|
196 | 11-mhz | 1
|
197 | liald₄ | 1
|
198 | 1.94× | 1
|